{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:52:10Z","timestamp":1789617130421,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ymthe.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:16:00Z","timestamp":1615680960000},"page":"1367-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gene therapy companies have an ethical obligation to develop expanded access policies"],"prefix":"10.1016","volume":"29","author":[{"given":"Lisa","family":"Kearns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Riley","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Moch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bateman-House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41587-019-0081-7","article-title":"What compassionate use means for gene therapies","volume":"37","author":"Chapman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1056\/NEJMhle1409465","article-title":"Practical, legal, and ethical issues in expanded access to investigational drugs","volume":"372","author":"Darrow","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.03.008_bib3","series-title":"FDA to facilitate access to unapproved drugs. BioCentury, December 14, 2018","author":"Usdin","year":"2018"},{"key":"10.1016\/j.ymthe.2021.03.008_bib4","series-title":"21st Century Cures Act: Public Law 114\u2013255\u2014Dec. 13, 2016","year":"2016"},{"key":"10.1016\/j.ymthe.2021.03.008_bib5","series-title":"Expanded access","year":"2020"},{"key":"10.1016\/j.ymthe.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/bcp.14284","article-title":"Expanded Access as a source of real-world data: An overview of FDA and EMA approvals","volume":"86","author":"Polak","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2021.03.008_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2021.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1477750920983571","article-title":"Siblings and discordant eligibility for gene therapy research: considering parental requests for non-trial \u201ccompassionate use.\u201d","author":"Webb","year":"2021","journal-title":"Clin Ethics."},{"key":"10.1016\/j.ymthe.2021.03.008_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2229-3485.173779","article-title":"Early access programs: Benefits, challenges, and key considerations for successful implementation","volume":"7","author":"Patil","year":"2016","journal-title":"Perspect. Clin. Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:59:23Z","timestamp":1761501563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1525001621001374"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.008","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy companies have an ethical obligation to develop expanded access policies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}